Inspire Medical Systems (NYSE:INSP) versus Co-Diagnostics (NASDAQ:CODX) Head to Head Comparison

Inspire Medical Systems (NYSE:INSPGet Free Report) and Co-Diagnostics (NASDAQ:CODXGet Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 4.1% of Inspire Medical Systems shares are held by insiders. Comparatively, 2.4% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inspire Medical Systems and Co-Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inspire Medical Systems -3.39% -3.93% -3.38%
Co-Diagnostics -518.69% -35.37% -32.58%

Volatility & Risk

Inspire Medical Systems has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.68, indicating that its share price is 168% less volatile than the S&P 500.

Valuation and Earnings

This table compares Inspire Medical Systems and Co-Diagnostics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inspire Medical Systems $624.80 million 10.75 -$21.15 million ($0.74) -299.50
Co-Diagnostics $6.81 million 5.37 -$35.33 million ($1.21) -0.97

Inspire Medical Systems has higher revenue and earnings than Co-Diagnostics. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inspire Medical Systems and Co-Diagnostics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inspire Medical Systems 0 4 9 0 2.69
Co-Diagnostics 0 1 0 0 2.00

Inspire Medical Systems presently has a consensus price target of $271.29, indicating a potential upside of 22.40%. Co-Diagnostics has a consensus price target of $2.50, indicating a potential upside of 113.68%. Given Co-Diagnostics’ higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Inspire Medical Systems.

Summary

Inspire Medical Systems beats Co-Diagnostics on 12 of the 14 factors compared between the two stocks.

About Inspire Medical Systems

(Get Free Report)

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

About Co-Diagnostics

(Get Free Report)

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.